Filing Flows › Royalty Pharma (RPRX) › Q2 2026 › vs Q2 2025
Royalty Pharma (RPRX) Q2 2026 vs Q2 2025 (year over year)
Royalty Pharma's revenue rose $95.5M (+16%) from $579M in Q2 2025 to $674M in Q2 2026. The biggest changes: Income from financial royalty assets +$87.6M (+16%); Other royalty income and revenues +$7.9M (+28%). Operating margin 19.7% against 36.3% (-16.5 pts).
Royalty Pharma, Q2 2026: revenue $674M (+16% year over year), operating margin 19.7%, net earnings $17.9M, operating cash flow $728M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 19.7% | 36.3% | -16.5 pts |
| Net margin | 2.7% | 5.6% | -2.9 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Income from financial royalty assets | $638M | $550M | $87.6M | +16% |
| Other royalty income and revenues | $36.1M | $28.2M | $7.9M | +28% |
| Revenue | $674M | $579M | $95.5M | +16% |
| Operating profit | $133M | $210M | −$76.7M | -37% |
| Costs & expenses | $541M | $369M | $172M | +47% |
| Pre-tax earnings | $81.5M | $92.6M | −$11.1M | -12% |
| Other expense, net | $51.6M | $117M | −$65.5M | -56% |
| Net earnings | $17.9M | $32.2M | −$14.3M | -44% |
| Minority interests | $63.6M | $60.5M | $3.1M | +5% |
| Depreciation | $1.3M | $1.4M | −$85K | -6% |
| Share-based compensation | $107M | $90.8M | $16.3M | +18% |
| Working capital & other | $602M | $240M | $363M | +151% |
| Operating cash flow | $728M | $364M | $364M | +100% |
Questions
How much did Royalty Pharma's revenue grow year over year in Q2 2026?
Royalty Pharma's revenue rose $95.5M (+16%) from $579M in Q2 2025 to $674M in Q2 2026.
What drove Royalty Pharma's revenue change in Q2 2026?
Income from financial royalty assets +$87.6M (+16%); Other royalty income and revenues +$7.9M (+28%).